LONDONâ€”GlaxoSmithKline PLC's diabetes treatment albiglutide was approved for use by U.S. regulators Tuesday, after a series of drug-development setbacks for the company.. Albiglutide was approved for use in Europe in March under the brand name Eperzan. It belongs to a class of drugs called GLP-1 receptor agonists, which work by stimulating the body's natural production of insulin and help regulate blood-sugar levels.. Glaxo...
  